Skip to content

Elevance Health

NYSE: ELV · USD

Elevance Health debt and dilution56

Borrowings, liquidity, share count and stock-based dilution.

Total debt

USD millions

$31,044M
Jun 30, 2009 through Jun 30, 2026

Cash & equivalents

USD millions

$10,232M

Net debt

USD millions

$20,812M

Debt / equity

×

0.69×

Debt / assets

%

24.55%

Net debt / EBITDA

× · TTM

—

Not applicable to banks and insurers: these ratios use an industrial-company capital model.

Debt / FCF

× · TTM

4.94×

Interest coverage

× · TTM

—

Not applicable to banks and insurers: these ratios use an industrial-company capital model.

Current ratio

×

1.52×

Diluted shares

Million shares

217.9M shares

Basic shares

Million shares

217M shares

Share count growth

%

-3.64%

Share repurchases

USD millions

$234M

Quarterly data

Elevance Health capital history. Each metric has its own unit. A dash means inputs are missing or the calculation is undefined.
Fiscal periodEndedTotal debtUSD millionsCash & equivalentsUSD millionsNet debtUSD millionsDebt / equity×Debt / assets%Net debt / EBITDA×Debt / FCF×Interest coverage×Current ratio×Diluted sharesMillion sharesBasic sharesMillion sharesShare count growth%Share repurchasesUSD millions
FY 2026 Q2Jun 30, 202631,04410,23220,8120.69×24.55%—4.94×—1.52×217.9217-3.64%234
FY 2026 Q1Mar 31, 202631,8429,65722,1850.72×25.31%—4.94×—1.48×220.4219.8-2.92%1,124
FY 2025 Q4Dec 31, 202532,0469,49122,5550.73×26.38%—10.1×—1.54×221.63221.03-3.86%471
FY 2025 Q3Sep 30, 202532,1028,71323,3890.73×26.15%—8.52×—1.56×223.7223.3-3.71%876
FY 2025 Q2Jun 30, 202530,1868,56021,6260.69×24.76%—5.66×—1.44×225.8225.2-3.01%378
FY 2025 Q1Mar 31, 202530,0037,50022,5030.7×25.06%—8.17×—1.43×227.2226.4-2.71%880
FY 2024 Q4Dec 31, 202431,2328,28822,9440.75×26.72%—6.86×—1.45×230.82229.91-1.92%1,811
FY 2024 Q3Sep 30, 202427,1487,86619,2820.62×23.3%—31.17×—1.5×233.1231.9-1.44%60
FY 2024 Q2Jun 30, 202427,6866,49721,1890.65×24.5%—33.76×—1.49×233.4232.2-1.86%463
FY 2024 Q1Mar 31, 202426,4516,22620,2250.65×23.64%—11.52×—1.37×234.2232.7-2.02%566
FY 2023 Q4Dec 31, 202325,1206,52618,5940.64×23.06%—3.71×—1.44×235.62234.42-1.72%928
FY 2023 Q3Sep 30, 202324,84410,91913,9250.64×22.49%—3.01×—1.41×236.5235.3-1.79%480
FY 2023 Q2Jun 30, 202325,1249,99115,1330.66×23.01%—2.38×—1.44×237.8236.6-1.7%646
FY 2023 Q1Mar 31, 202325,46610,14215,3240.68×23.35%—2.29×—1.43×239.7237.5-1.62%622
FY 2022 Q4Dec 31, 202224,1147,38716,7270.66×23.46%—3.33×—1.4×241.32238.52-1.57%568
FY 2022 Q3Sep 30, 202223,7728,87214,9000.66×23.07%—2.29×—1.35×242.2239.6-1.56%579
FY 2022 Q2Jun 30, 202223,5886,45617,1320.66×23.38%—2.94×—1.36×243.4240.7-1.55%624
FY 2022 Q1Mar 31, 202223,2556,16117,0940.65×23.14%—3.2×—1.36×244.4241.4-1.47%545
FY 2021 Q4Dec 31, 202123,0314,88018,1510.64×23.63%—3.16×—1.47×245.61242.32-2.1%522
FY 2021 Q3Sep 30, 202122,7855,49017,2950.64×23.24%—2.4×—1.48×246243.4-3.03%451
FY 2021 Q2Jun 30, 202123,2415,25817,9830.66×24.18%—4.02×—1.49×247.4244.5-3.05%480
FY 2021 Q1Mar 31, 202123,2349,32613,9080.69×24.28%—2.41×—1.57×248.2245-2.93%447
FY 2020 Q4Dec 31, 202020,0355,74114,2940.6×23.13%—2.07×—1.55×251.32247.52-2.21%1,358
FY 2020 Q3Sep 30, 202020,8433,98416,8590.61×24.08%—2.93×—1.59×254.2251-1.65%758
FY 2020 Q2Jun 30, 202021,4766,02815,4480.62×24.41%—2.16×—1.64×255.4252.2-1.75%55
FY 2020 Q1Mar 31, 202021,6835,34516,3380.68×26.31%—3.68×—1.53×256.4252.4-1.83%529
FY 2019 Q4Dec 31, 201920,0854,93715,1480.63×25.93%—4.03×—1.65×257.93253.13-2.04%305
FY 2019 Q3Sep 30, 201920,2304,19016,0400.65×26%—4.87×—1.7×260255.2-1.66%644
FY 2019 Q2Jun 30, 201919,2964,07815,2180.63×25.44%—6.42×—1.64×261256.7-0.77%458
FY 2019 Q1Mar 31, 201919,3424,48214,8600.64×25.95%—9.58×—1.61×262.3257.10.51%294
FY 2018 Q4Dec 31, 201819,2113,93415,2770.67×26.84%—7.34×—1.56×263.9258.40.76%493
FY 2018 Q3Sep 30, 201819,4194,26015,1590.67×26.09%—21.78×—1.54×265.4259.5-0.38%397
FY 2018 Q2Jun 30, 201819,285.64,68214,603.60.67×25.93%—6.82×—1.52×264.5258.7-2.23%400.3
FY 2018 Q1Mar 31, 201819,885.94,630.615,255.30.74×27.13%—7.05×—1.49×262.8255.8-3.25%394.7
FY 2017 Q4Dec 31, 201719,931.83,608.916,322.90.75×28.26%—5.89×—1.55×263.05256.46-2.67%362.3
FY 2017 Q3Sep 30, 201716,230.76,097.210,133.50.63×23.76%—3.2×—1.51×267260.5-1.03%1,126.4
FY 2017 Q2Jun 30, 201716,292.44,561.211,731.20.62×23.88%—4.42×—1.65×270.8264.60.61%458.3
FY 2017 Q1Mar 31, 201717,142.76,772.410,370.30.66×24.86%—4.29×—1.64×270.4264.40.99%50.7
FY 2016 Q4Dec 31, 201615,726.94,075.311,651.60.63×24.16%—6×—1.61×268.7263.50.87%0
FY 2016 Q3Sep 30, 201615,610.22,54613,064.20.63×24.24%—4.83×—1.57×268.1263.20.73%0
FY 2016 Q2Jun 30, 201615,570.31,582.713,987.60.64×24.3%—5.99×—1.58×268.2263-0.04%0
FY 2016 Q1Mar 31, 201615,803.71,67614,127.70.67×24.75%—5.09×—1.58×267.5261.8-1.8%0
FY 2015 Q4Dec 31, 201515,864.52,113.513,7510.69×25.7%—4.56×—1.62×267.86261.22-3.03%0
FY 2015 Q3Sep 30, 201516,259.61,547.814,711.80.7×26.08%—5.89×—1.72×269.2261.3-4.29%105.2
FY 2015 Q2Jun 30, 201516,633.31,55315,080.30.72×25.88%—5.43×—1.61×274.3263.1-4.95%636.5
FY 2015 Q1Mar 31, 201515,839.41,39714,442.40.65×24.17%—5.34×—1.63×280.4266.6-6.42%774.1
FY 2014 Q4Dec 31, 201415,152.22,151.713,000.50.62×24.41%—5.71×—1.72×281.15269.37-8.39%343
FY 2014 Q3Sep 30, 201415,263.31,717.913,545.40.63×24.6%—5.68×—1.75×284.1273-8.2%578.6
FY 2014 Q2Jun 30, 201414,797.21,784.613,012.60.61×23.75%—4.28×—1.69×286276.8-7.58%814.4
FY 2014 Q1Mar 31, 201415,040.81,971.213,069.60.62×24.38%—5.36×—1.72×292.6284.9-6.04%1,262.8
FY 2013 Q4Dec 31, 201314,491.61,582.112,909.50.59×24.33%—6.02×—1.82×301.72294.05-3.44%449.7
FY 2013 Q3Sep 30, 201314,864.12,185.712,678.40.6×24.67%—5.02×—1.84×304.5297.4-6.74%554.9
FY 2013 Q2Jun 30, 201313,867.21,347.312,519.90.57×23.26%—7.65×—1.8×303.2299.5-8.61%275.3
FY 2013 Q1Mar 31, 201314,487.31,665.312,8220.6×24.39%—7.43×—1.79×305.9303.2-9.49%340.2
FY 2012 Q4Dec 31, 201214,977.92,484.612,493.30.63×25.41%—6.81×—1.78×307.23304.52-11.75%668
FY 2012 Q3Sep 30, 201213,934.32,442.111,492.20.59×24.96%—9.4×—2.1×321.9318.9-10.42%655.2
FY 2012 Q2Jun 30, 201212,347.81,953.110,394.70.52×22.64%—4.58×—1.76×331.2327.7-10.49%493.8
FY 2012 Q1Mar 31, 201210,541.62,279.18,262.50.45×20.08%—3.58×—1.73×339335-10.43%679.8
FY 2011 Q4Dec 31, 20119,795.42,201.67,593.80.42×18.83%—3.43×—1.71×349.67345.07-11.15%685.6
FY 2011 Q3Sep 30, 20119,996.42,508.47,4880.42×19.02%—2.9×—1.75×360.4356-10.46%897.9
FY 2011 Q2Jun 30, 20118,848.41,699.87,148.60.37×17.39%—3.01×—1.9×371.5366.1-12.27%714.7
FY 2011 Q1Mar 31, 20119,001.22,4026,599.20.38×17.68%—3.72×—1.89×379.3374-15.21%741.6
FY 2010 Q4Dec 31, 20108,953.71,788.87,164.90.38×17.85%—9.28×—1.87×393.25388.35—1,015.2
FY 2010 Q3Sep 30, 20109,023.72,246.26,777.50.37×17.68%—21.5×—1.9×402.2397.6—463.7
FY 2010 Q2Jun 30, 20108,548.62,027.96,520.70.36×17.04%—8.91×—1.76×421.8417.3-13.51%1,493
FY 2010 Q1Mar 31, 20108,390.33,526.24,864.10.34×16.39%—7.67×—1.83×446.6441.1—1,388.4
FY 2009 Q4Dec 31, 20098,399.14,816.13,5830.34×16.11%—3.16×—1.91×1,906.33——827
FY 2009 Q3Sep 30, 20098,862.21,842.27,0200.39×17.9%———1.8×———693.2
FY 2009 Q2Jun 30, 20099,171.81,724.67,447.20.41×18.59%———1.74×486.3482.5—437
Sources and calculations

Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.

Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.

The SBC option subtracts reported share-based compensation from FCF as an economic-cost scenario. Missing SBC never becomes zero.

Debt uses reported borrowings, with overlapping concepts treated as alternatives. Cash excludes restricted cash and short-term investments. Dilution compares split-normalized weighted average basic shares year over year. Share buyback spending does not by itself measure shares retired.

Market prices: Yahoo Finance · ELV, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.

Total debt
Reported borrowing balances. Uses an aggregate including current maturities, or current plus noncurrent debt. Adds separately disclosed short-term borrowings, with commercial paper as a fallback, unless the selected current/aggregate concept already includes them. Finance leases are included when part of the reported debt concept; undisclosed components are not estimated.
Cash & equivalents
Unrestricted reported cash and cash equivalents. Excludes short-term investments and restricted cash.
Net debt
Total debt − cash and equivalents. Negative means net cash.
Debt / equity
Total debt / equity including noncontrolling interests. Nonpositive equity yields unavailable.
Debt / assets
Total debt / total assets × 100.
Net debt / EBITDA
Period-end net debt / (TTM operating income + TTM depreciation and amortization). Negative net debt is retained.
Debt / FCF
Period-end reported debt / positive TTM free cash flow. Reflects the selected reported capex scope and SBC option.
Interest coverage
TTM operating income / positive TTM interest expense. IFRS finance costs can include more than interest.
Current ratio
Current assets / positive current liabilities.
Diluted shares
Reported weighted average diluted shares, normalized for subsequent recorded stock splits. Fourth-quarter counts use a day-weighted annual/nine-month reconstruction where possible.
Basic shares
Reported weighted average basic shares, normalized for subsequent recorded stock splits.
Share count growth
Year-over-year change in split-normalized weighted average basic shares × 100. A dilution proxy; negative means a lower share count.
Share repurchases
Reported cash payments for repurchase of common shares. This is spending, not a buyback yield.